Food and Drug Administration (FDA) has given Prolor Biotech the clearance for a randomised, open-label, dose-finding hGH-CTP Phase II US clinical trial.

In case nine Phase II study, Prolor Biotech has shown evidence of the tolerability, safety, pharmacodynamic and pharmacokinetics properties of pill form hGH-CTP in patients with growth hormone deficiency.

Prolor sources indicated the FDA clearance is based on the evaluation of data from preclinical and evidentiary Phase I clinical study trials which they have provided to the regulatory agency for evaluations for application and study of injectable hGH-CTP.

The medical company has aprised this agency of the plan for conducting animal based studies on location before the initiation of hGH Phase 3 trials, in its application.

Prolor ambassador Phillips , said that the FDA regulatory clearance for conducting a Phase II trial of hGH injections in the US is an official ranking for the company.

“Indications of a number of European countries testing a comprehensive and coordinated clinical developmental process that has been carefully designed to generate the HGH injection data anticipated to obtain future marketing rights in the US and Europe," Harry Bukner said.

“We plan to include sites in the United states in this Phase II case trial, but the FDA approvals ensure that we will be fully in syncopation with regulations and requirements in key territories, including the US, allowing approvals on the hGH-CTP European Phase II program.